VivoSeq
Infectious Disease

Helicobacter Pylori Infectious Disease

13

Pipeline Programs

0

Active Trials

8

Companies Involved

Helicobacter pylori infectious disease is an emerging landscape with 13 programs across 8 companies. The most active players are Salix, Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., Dexcel Pharma Technologies Ltd.. 9 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

45/100

Completion Rate

N/A

Attrition Rate

N/A

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)